Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Fresenius Medical Care AG & Co. KGaA Stock Performance
Fresenius Medical Care AG & Co. KGaA stock traded down $0.23 during trading hours on Thursday, reaching $18.16. 736,552 shares of the stock were exchanged, compared to its average volume of 627,055. The stock has a market cap of $10.64 billion, a P/E ratio of 11.71, a P/E/G ratio of 0.93 and a beta of 1.02. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.85 and a current ratio of 1.18. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $18.05 and a 52-week high of $40.45. The firm's 50 day moving average is $22.68 and its 200 day moving average is $28.80.
Analysts Set New Price Targets
Several research analysts have recently issued reports on FMS shares. StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, July 15th. Truist Financial lowered their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a report on Wednesday, June 22nd. JPMorgan Chase & Co. reduced their price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. Berenberg Bank reduced their price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a research report on Wednesday, August 10th. Finally, DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $45.83.